Bayer AG / Analyst ratings
Price targets
Analyst ratings
8 analysts rated this company in the past 90 days. The average target price is €26.88, this is a change of +0.5% compared to the current price.
-
UBS maintains Bayer at 'Neutral' - Target 26 euros
ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for Bayer at "Neutral" with a price target of €26. In an industry study released Monday, Geoff Haire examined the positioning of US investors in the chemicals sector. The focus is on earnings risks for fiscal year 2025 and potential drivers for an earnings recovery in the coming fiscal year. Investors appeared to doubt the industry's ability to achieve revenue growth and double-digit earnings growth in 2026./tih/gl
Publication of the original study: September 12, 2025 / 3:37 p.m. / GMT First distribution of the original study: September 12, 2025 / 3:37 p.m. / GMT
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Jefferies maintains Bayer's 'Hold' rating - target €25
NEW YORK (dpa-AFX Analyst) - The analyst firm Jefferies has maintained a "Hold" rating on Bayer following a fundamental agreement to settle further PCB cases at the Sky Valley Education Center in Washington State. The price target remains at €25. Analyst Chris Counihan sees the agreement as "a step toward reducing PCB litigation risk," as he wrote in a report published Monday. The settlements are fully covered by the €530 million PCB-related provision recognized in the second quarter of 2025, which also takes into account the Burke case and other related costs. The nine previous rulings, which affected 49 plaintiffs, are still pending appeal, so a certain residual risk still exists./rob/ck/he
Publication of the original study: August 18, 2025 / 8:44 a.m. / Time zone not specified in the study. First distribution of the original study: August 18, 2025 / 8:44 a.m. / Time zone not specified in the study.
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
UBS raises target for Bayer to 26 euros - 'Neutral'
ZURICH (dpa-AFX Analyst) - Swiss bank UBS raised its price target for Bayer from €24 to €26 following the recently presented detailed quarterly figures. The rating was left at "Neutral." The final results showed a higher contribution from the anticoagulant Xarelto to the company's results, wrote Matthew Weston in a review published Thursday. In addition, the kidney drug Kerendia has experienced higher growth, especially in China./rob/la/bek
Publication of the original study: August 13, 2025 / 3:19 PM / GMT
First distribution of the original study: August 13, 2025 / Time not specified in study / Time zone not specified in study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Berenberg maintains Bayer on 'Hold' - target 26 euros
HAMBURG (dpa-AFX Analyst) - Private bank Berenberg has maintained its "Hold" rating for Bayer with a price target of €26. Lower corn prices and difficulties regaining market share for the weed killer Dicamba have made it cautious, Sebastian Bray wrote in a study released Tuesday. He is skeptical whether the pharmaceutical and agrochemical group will be able to achieve the consensus estimate for operating earnings (EBITDA) in 2026./rob/bek
Publication of the original study: August 11, 2025 / 4:22 PM / GMT
First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Goldman raises target for Bayer to 35 euros - 'Buy'
NEW YORK (dpa-AFX Analyst) - Following final second-quarter results, US investment bank Goldman Sachs raised its price target for Bayer from €34 to €35 and maintained its "Buy" rating. James Quigley expressed surprise at the extent of the share price decline on the reporting day in a study released Thursday. The previously published key data had largely been confirmed, and he saw progress in terms of legal disputes./tih/la
Publication of the original study: August 6, 2025 / 5:06 a.m. / BST
First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
UBS maintains Bayer at 'Neutral' - Target 24 euros
ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for Bayer at "Neutral" with a price target of €24 following detailed figures. Following last week's preliminary figures, the price reaction was muted, wrote Matthew Weston in a quick assessment released Wednesday. Investors were primarily awaiting two key catalysts: Phase III data for Asundexian in the Oceanic Stroke case and the next steps in the glyphosate litigation before the U.S. Supreme Court in the Durnel/rob/ck/bek case.
Publication of the original study: August 6, 2025 / 6:52 a.m. / GMT
First distribution of the original study: August 6, 2025 / Time not specified in study / Time zone not specified in study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
JPMorgan leaves Bayer at 'Neutral'
NEW YORK (dpa-AFX Analyst) - Following detailed figures, US bank JPMorgan has maintained its rating for Bayer at "Neutral" with a price target of €25. Most of the information is already known, wrote Richard Vosser in a quick assessment released Wednesday. He sees only limited need for an adjustment to the consensus estimate for operating profit. Overall, however, the fact that the better-than-expected performance is partly related to the pharmaceutical hit Xarelto and the sale of a football player by Bayer 04 Leverkusen may be disappointing for some./rob/ck/mis
Publication of the original study: August 6, 2025 / 9:09 a.m. / BST
First distribution of the original study: August 6, 2025 / 9:09 a.m. / BST
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Jefferies maintains Bayer's 'Hold' rating - target €25
NEW YORK (dpa-AFX Analyst) - The analyst firm Jefferies has maintained its "Hold" rating for Bayer after the company's earnings release, with a price target of €25. The results are in line with the recently announced key figures, wrote Chris Counihan in a study released Wednesday. He expects a muted price reaction./rob/tih/bek
Publication of the original study: August 6, 2025 / 1:51 a.m. / Time zone not specified in the study
First distribution of the original study: August 6, 2025 / 1:51 a.m. / Time zone not specified in the study
Note: Information on the disclosure obligation for conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Bernstein maintains Bayer at 'Market Perform' - Target 30 euros
NEW YORK (dpa-AFX Analyst) - US analyst Bernstein Research has maintained its rating for Bayer at "Market-Perform" with a price target of €30. While the price reductions for many drugs demanded by US President Donald Trump would be a further burden for pharmaceutical companies in addition to the US tariffs, they would also be manageable, Florent Cespedes wrote in a study released Friday. The requested actions appear to be limited to Medicaid. This is a government-funded healthcare program for low-income people, the elderly, and people with disabilities./mis/nas
Publication of the original study: August 1, 2025 / 7:10 a.m. / UTC
First distribution of the original study: August 1, 2025 / 7:10 a.m. / UTC
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Jefferies maintains Bayer's 'Hold' rating - target €25
NEW YORK (dpa-AFX Analyst) - The analyst firm Jefferies has maintained its rating for Bayer at "Hold" with a price target of €25 following key second-quarter figures. Chris Counihan, the new analyst responsible for the chemical and pharmaceutical company, highlighted the raised target for this year's operating result (EBITDA) in a study released Friday. At the segment level, exceeded expectations are related to the agricultural business./tih/nas
Publication of the original study: August 1, 2025 / 2:06 a.m. / ET
First distribution of the original study: August 1, 2025 / 2:06 a.m. / ET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
JPMorgan leaves Bayer at 'Neutral' - Target 25 euros
NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained its rating for Bayer at "Neutral" with a price target of €25 following preliminary quarterly figures. Sales were slightly lower than market expectations, wrote Richard Vosser in an initial reaction released Friday. However, the pharmaceutical and agrochemical group's operating result exceeded the consensus estimate by 12 percent on an adjusted basis./rob/edh/la
Publication of the original study: August 1, 2025 / 12:17 AM / BST
First distribution of the original study: August 1, 2025 / 12:17 AM / BST
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Bernstein maintains Bayer at 'Market Perform' - Target 30 euros
NEW YORK (dpa-AFX Analyst) - US analyst firm Bernstein Research has maintained its rating for Bayer at "Market-Perform" with a price target of €30. Florent Cespedes wrote in an industry study released Monday that the US would apparently impose tariffs of 15 percent on brand-name drugs, while generics would apparently not be affected. Overall, the risks for the companies appear manageable, with the impact on the companies' profits potentially reaching a low- to mid-single-digit percentage. Novo Nordisk would be least affected, and UCB likely the most./mis/jha/
Publication of the original study: July 28, 2025 / 6:49 a.m. / UTC
First distribution of the original study: July 28, 2025 / 6:49 a.m. / UTC
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
UBS maintains Bayer at 'Neutral' - Target 24 euros
ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained a "neutral" rating on Bayer with a price target of €24. Looking ahead to the company's quarterly results on August 6, its estimates for sales and underlying EBITDA are slightly below consensus forecasts, Matthew Weston wrote in an outlook released Thursday. The legal disputes surrounding the weed killer Roundup remain the most important topic for the investment background - however, he does not expect any significant news on this matter./rob/gl/mis
Publication of the original study: July 23, 2025 / 11:53 PM / GMT. First distribution of the original study: July 24, 2025 / Time not specified in study / Time zone not specified in study.
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
JPMorgan leaves Bayer at 'Neutral' - Target 25 euros
NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained its rating for Bayer at "Neutral" with a price target of €25. Its sales forecast is one percent below the consensus estimate, Richard Vosser wrote in an outlook on the second-quarter figures released Monday. The expert expects the pharmaceutical and agrochemical group's operating result (EBITDA) to be in line with the average analyst forecast./rob/edh/ajx
Publication of the original study: July 21, 2025 / 3:46 PM / BST
First distribution of the original study: July 21, 2025 / 3:46 PM / BST
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Jefferies raises target for Bayer to 25 euros - 'Hold'
NEW YORK (dpa-AFX Analyst) - The analyst firm Jefferies raised its price target for Bayer from €22 to €25 in light of the upcoming quarterly results, but maintained its "Hold" rating. Charlie Bentley justified the higher price target on Friday with the positive impact of the weakness of the U.S. dollar against the euro observed since the beginning of the year. This one-time effect will reduce the agrochemical and pharmaceutical company's net debt. Further debt reduction appears to depend primarily on the resolution of legal disputes and the review of fundamental changes to the product portfolio./rob/la/he
Publication of the original study: July 11, 2025 / 9:02 a.m. / Time zone not specified in the study. First distribution of the original study: July 11, 2025 / 11:30 a.m. / Time zone not specified in the study.
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
JPMorgan leaves Bayer at 'Neutral' - Target 25 euros
NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained its rating for Bayer at "Neutral" with a price target of €25. In his outlook for the quarterly report published on Monday, Richard Vosser expects the Leverkusen-based company's results to largely meet expectations. The sales target is likely to be raised due to the pharmaceuticals business, although this will ultimately be more than offset by currency effects. Overall, the report is likely to result in slightly lower market expectations./rob/ag/gl
Publication of the original study: July 6, 2025 / 9:15 PM / BST First distribution of the original study: July 7, 2025 / 12:15 AM / BST
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Goldman raises target for Bayer to 34 euros - 'Buy'
NEW YORK (dpa-AFX Analyst) - US investment bank Goldman Sachs raised its price target for Bayer from €33 to €34 and maintained its "Buy" rating. Damping currency effects masked the pharmaceutical company's strength, wrote James Quigley in his outlook for the quarterly report released Friday. The timing of the statement by the US government's representative (Solicitor General) in the glyphosate case is in focus./ag/gl
Publication of the original study: July 4, 2025 / 5:05 a.m. / BST First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
JPMorgan leaves Bayer at 'Neutral' - Target 25 euros
NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained its rating for Bayer at "Neutral" with a price target of €25. Analyst Richard Vosser discussed the US Supreme Court's decision to seek the government's opinion in the glyphosate dispute in a study released Monday. Although it is positive that the Durnell case has not been dismissed outright, a possible short-term resolution of the legal dispute at the federal level is being delayed./tih/stw
Publication of the original study: June 30, 2025 / 4:47 PM / BST
First distribution of the original study: June 30, 2025 / 4:47 PM / BST
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Jefferies maintains Bayer on 'Hold' - target 22 euros
NEW YORK (dpa-AFX Analyst) - Following news of the US glyphosate dispute, analyst Jefferies has maintained a "Hold" rating on Bayer with a price target of €22. The fact that the US Supreme Court wants to seek the opinion of the US government and has therefore requested an opinion from the Solicitor General is delaying a potentially favorable outcome for the agricultural chemicals company, analyst Charlie Bentley wrote in a study published Monday. However, this is not the worst-case scenario for Bayer. If the court ultimately accepts the case, a positive decision could still be made by June 2026./rob/ck/stw
Publication of the original study: June 30, 2025 / 10:52 AM / Time zone not specified in the study
First distribution of the original study: June 30, 2025 / 10:52 AM / Time zone not specified in the study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Berenberg maintains Bayer on 'Hold' - target 26 euros
HAMBURG (dpa-AFX Analyst) - Private bank Berenberg has maintained a "Hold" rating on Bayer with a price target of €26. Products based on biological mechanisms of action (biologics) are rapidly developing into an important product group for crop protection manufacturers, who are facing major challenges, wrote Aron Ceccarelli in a study on the chemical industry published Friday. In the medium term, prices for row-crop crops are likely to decline. Although profitability in agriculture has improved since the beginning of the war in Ukraine, he noted, increasing corn acreage in the US and improvements in global yields could lead to price declines starting in 2026. In the long term, the main problem for the traditional pesticide industry, dominated by Corteva, Syngenta, FMC, Bayer, and BASF, is the lack of volume growth. The growing biologics segment, on the other hand, is significantly more fragmented, and Corteva is best positioned here.
Publication of the original study: June 26, 2025 / 4:26 PM / GMT. First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study.
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Goldman upgrades Bayer to 'Buy' - target raised to 33 euros
NEW YORK (dpa-AFX Analyst) - US investment bank Goldman Sachs has raised its price target for Bayer shares from €29.10 to €33 and upgraded the stock from "Neutral" to "Buy." James Quigley sees a favorable risk-reward ratio for the Leverkusen-based company for the second half of 2025. This also applies in view of further news regarding the legal disputes, he wrote in his buy recommendation published on Thursday./ag/tih
Publication of the original study: June 5, 2025 / 5:00 a.m. / BST
First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Barclays raises target for Bayer to 25 euros - 'Equal Weight'
LONDON (dpa-AFX Analyst) - British investment bank Barclays has raised its price target for Bayer from €22 to €25, but maintained its rating at "Equal Weight." Thanks to the strong performance of its pharmaceuticals business in the first quarter, the Leverkusen-based company could exceed its annual targets in this area, Emily Field wrote in his commentary on Tuesday. The agricultural and consumer businesses are now well on track to achieve their targets./ag/gl
Publication of the original study: May 27, 2025 / 3:25 a.m. / GMT First distribution of the original study: May 27, 2025 / 3:29 a.m. / GMT
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
UBS maintains Bayer at 'Neutral' - Target 24 euros
ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for Bayer at "Neutral" with a price target of €24. Investors are currently looking for safety, which is rare in the chemicals sector, analyst Geoff Haire wrote on Friday afternoon. Meanwhile, investors are questioning potential downside risks in the cyclical sector, with BASF being the generally preferred alternative. However, economic stimulus programs and capacity cuts are not yet a reason to generally invest in cyclical stocks./tih/ag
Publication of the original study: May 23, 2025 / 4:50 PM / GMT
First distribution of the original study: May 23, 2025 / 4:50 PM / GMT
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
JPMorgan leaves Bayer at 'Neutral' - Target 25 euros
NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained a "neutral" rating on Bayer with a price target of €25. Following the pharmaceutical and agrochemical company's strong quarterly results, it has moderately raised its estimates, Richard Vosser wrote in a commentary released Thursday. In the short term, however, the focus remains on the legal disputes surrounding glyphosate-containing fertilizers and the chemical PCB./rob/gl/tih
Publication of the original study: May 14, 2025 / 8:52 PM / BST
First distribution of the original study: May 15, 2025 / 12:15 AM / BST
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
UBS maintains Bayer at 'Neutral' - Target 22 euros
ZURICH (dpa-AFX Analyst) - Following Bayer's quarterly results, the Swiss major bank UBS maintained its "neutral" rating with a price target of €22. The pharmaceuticals business performed well, but must cope with the patent expiration for Xarelto and the market launch of new drugs, Jo Walton wrote in an initial reaction on Tuesday. In the agrochemicals sector, Bayer also continues to struggle with the suspended approval for dicamba-based weed killers in the US, Chinese competition for the weed killer glyphosate, and a generally stagnant market. However, all of this is already reflected in the valuation, which is overshadowed by the ongoing glyphosate litigation in the US./rob/gl/edh
Publication of the original study: May 13, 2025 / 7:32 a.m. / GMT First distribution of the original study: May 13, 2025 / Time not specified in study / Time zone not specified in study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
JPMorgan leaves Bayer at 'Neutral' - Target 25 euros
NEW YORK (dpa-AFX Analyst) - Following Bayer's first-quarter results, US bank JPMorgan has maintained its rating of "Neutral" with a price target of €25. According to an initial assessment released Tuesday, Richard Vosser sees "strong results" and pointed to the confirmed annual outlook. This should be well-received by investors, he wrote./mis/edh
Publication of the original study: May 13, 2025 / 7:42 a.m. / BST
First distribution of the original study: May 13, 2025 / 7:42 a.m. / BST
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Deutsche Bank Research maintains Bayer's 'Hold' rating - target €23
FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research has maintained its rating for Bayer at "Hold" with a price target of €23 following the company's earnings release. The agrochemical and pharmaceutical company exceeded expectations in the first quarter, Falko Friedrichs wrote in a study released Tuesday. This, along with the confirmed outlook without currency effects, is encouraging news. However, on an adjusted basis, the Leverkusen-based company's performance remains weak, and legal risks remain. It also remains to be seen how Bayer will fare in the currently volatile economic environment./tih/mis
Publication of the original study: May 13, 2025 / Time not specified in the study / GMT
First distribution of the original study: May 13, 2025 / 6:39 a.m. / GMT
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Jefferies maintains Bayer's 'Hold' rating after figures
NEW YORK (dpa-AFX Analyst) - The analyst firm Jefferies has maintained its "Hold" rating for Bayer after the company's earnings release, with a price target of €22. In a quick assessment released Tuesday, analyst Charlie Bentley particularly praised the company's adjusted operating profit and, in particular, the strong performance of the pharmaceuticals business. The agricultural division also exceeded lowered estimates, while the over-the-counter medicines business missed expectations on the earnings side. Overall, he expects a positive price reaction./rob/ck/mis
Publication of the original study: May 13, 2025 / 2:00 a.m. / ET
First distribution of the original study: May 13, 2025 / 2:00 a.m. / ET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
UBS maintains Bayer at 'Neutral' - Target 22 euros
ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained a "neutral" rating on Bayer with a price target of €22. The quarterly results presentation on May 13 will likely focus on progress in the litigation in the agrochemicals division, the division's momentum, and the impact of US tariffs, Jo Walton wrote in an outlook released Friday. In the pharmaceutical business, he is awaiting an update on the impact of the expiration of patent protection for the blood thinner Xarelto./rob/gl/la
Publication of the original study: May 8, 2025 / 2:52 PM / GMT. First distribution of the original study: May 8, 2025 / Time not specified in study / Time zone not specified in study.
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
JPMorgan leaves Bayer at 'Neutral' - Target 25 euros
NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained its rating for Bayer at "Neutral" with a price target of €25. Results are likely to be slightly below consensus given weaker agricultural chemicals sales, analyst Richard Vosser wrote in his outlook for the company's mid-May quarterly report, published Tuesday. However, the annual targets are likely to remain unchanged./ag/la
Publication of the original study: April 21, 2025 / 7:42 PM / BST
First distribution of the original study: April 22, 2025 / 12:15 AM / BST
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Bernstein maintains Bayer at 'Market Perform' - Target 30 euros
NEW YORK (dpa-AFX Analyser) - The US analyst firm Bernstein Research has maintained its rating for Bayer at "Market-Perform" with a price target of 30 euros in light of the threat of massive US tariffs on imported pharmaceuticals. The tariffs announced by US President Donald Trump pose the risk of slaughtering the "golden goose" for European pharmaceutical companies, wrote analyst Florent Cespedes in an industry study released Wednesday./edh/he
Publication of the original study: April 9, 2025 / 1:33 p.m. / UTC First distribution of the original study: April 9, 2025 / 1:33 p.m. / UTC
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Jefferies maintains Bayer on 'Hold' - target 22 euros
NEW YORK (dpa-AFX Analyst) - The analyst firm Jefferies has maintained its rating for Bayer at "Hold" with a price target of €22. The company had previously filed a US glyphosate case for review with the US Supreme Court. Although the chances of success are slim, a victory in the court would significantly limit Bayer's risks in the legal disputes, analyst Charlie Bentley wrote on Monday. That would then be a strong price driver./mis/ag
Publication of the original study: April 7, 2025 / 2:33 a.m. / ET
First distribution of the original study: April 7, 2025 / 2:33 a.m. / ET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
JPMorgan leaves Bayer at 'Neutral' - Target 25 euros
NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained its rating for Bayer at "Neutral" with a price target of €25. Analyst Richard Vosser, in a study released Monday, called it "slightly positive" that the pharmaceutical and agrochemical company has turned to the US Supreme Court for a review of the glyphosate "Durnell" case. He noted the increased likelihood that the court will hear the case to resolve conflicting rulings. However, a hearing is still unclear, and it is also uncertain whether the decision will be in favor of Bayer./ck/mis
Publication of the original study: April 7, 2025 / 3:03 AM / BST
First distribution of the original study: April 7, 2025 / 3:03 AM / BST
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Goldman maintains Bayer at 'Neutral' - Target 29 euros
NEW YORK (dpa-AFX Analyst) - US investment bank Goldman Sachs has maintained its rating for Bayer at "Neutral" with a price target of €29. The negative jury decision by the court in the US state of Georgia in the glyphosate dispute is disappointing, analyst James Quigley wrote on Monday. However, recent legislative changes in the state could prevent new disputes./ag/bek
Publication of the original study: March 24, 2025 / 9:53 a.m. / GMT
First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
JPMorgan leaves Bayer at 'Neutral' - Target 25 euros
NEW YORK (dpa-AFX Analyst) - Following a guilty verdict in the lawsuit over the glyphosate-based weed killer Roundup, U.S. bank JPMorgan has maintained a "neutral" rating on Bayer with a price target of €25. The agrochemical and pharmaceutical company is likely to appeal the verdict of a U.S. jury that ordered it to pay nearly $2.1 billion in damages, analyst Richard Vosser wrote in a study published Monday. While lawyers for other plaintiffs may feel encouraged by the verdict, the fundamental situation for Bayer has not changed significantly. Bayer's planned appeal to the US Supreme Court to fundamentally clarify the glyphosate issue remains the focus./gl/mis
Publication of the original study: March 23, 2025 / 11:06 PM / GMT. First distribution of the original study: March 24, 2025 / 12:15 AM / GMT
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Bernstein maintains Bayer at 'Market Perform' - Target 30 euros
NEW YORK (dpa-AFX Analyst) - US analyst firm Bernstein Research has maintained its rating for Bayer at "Market-Perform" with a price target of €30. Following the presentation of its annual results in early March, analyst Florent Cespedes wrote in a report released Thursday that he has lowered his expectations for the pharmaceutical and agricultural chemicals company due to a more difficult business environment. With regard to a possible resolution of the US glyphosate litigation, there is unlikely to be any further clarity before next year./mis/gl
Publication of the original study: March 20, 2025 / 11:20 a.m. / UTC First distribution of the original study: March 20, 2025 / 4:36 p.m. / UTC
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
JPMorgan leaves Bayer at 'Neutral' - Target 25 euros
NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained its rating for Bayer at "Neutral" with a price target of €25. Following the financial results, the focus will again be on news regarding the settlement of the legal disputes in the US, wrote analyst Richard Vosser in his commentary published on Monday. A Supreme Court decision in the PCB area could come as early as May, but it could also take until 2026. In the glyphosate case, it is still completely unclear when the appropriate appeal will be brought before the US Supreme Court./ag/edh
Publication of the original study: March 16, 2025 / 11:10 PM / GMT
First distribution of the original study: March 17, 2025 / 12:15 AM / GMT
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Berenberg raises target for Bayer to 26 euros - 'Hold'
HAMBURG (dpa-AFX Analyst) - Private bank Berenberg has raised its price target for Bayer from €22 to €26 and maintained its "Hold" rating. Analyst Sebastian Bray warmed somewhat to the shares of the agrochemical and pharmaceutical company in a study published Monday, noting that there is a chance of recovery in some areas. Assuming that agricultural commodity prices do not collapse in the event of a peace agreement between Russia and Ukraine, further risks to Bayer's earnings should be limited. For the time being, however, the US legal disputes with their uncertain outcome speak against a buy recommendation./tih/mis
Publication of the original study: March 9, 2025 / 1:39 PM / GMT
First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
UBS maintains Bayer at 'Neutral' - Target 22 euros
ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for Bayer at "Neutral" with a price target of €22 on the occasion of a possible new share issue. Analyst Jo Walton wrote in a report released Friday that he sees this as a further step toward a possible settlement of legal disputes in the US. However, the expert does not believe this measure will be necessary if Bayer's current efforts to change the law at the federal level are successful or if the U.S. Supreme Court intervenes./la/edh
Publication of the original study: March 7, 2025 / 3:37 p.m. / GMT First distribution of the original study: March 7, 2025 / 3:37 p.m. / GMT
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
UBS maintains Bayer at 'Neutral' - Target 22 euros
ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for Bayer at "Neutral" with a price target of €22. The 2024 financial figures were in line with recently adjusted market expectations, analyst Jo Walton wrote in his in-depth review on Thursday. Bayer performed slightly better in the pharmaceuticals business and in operating free cash flow. The only disappointment is the forecast of lower free cash flow this year./bek/ag
Publication of the original study: March 6, 2025 / 6:34 a.m. / GMT
First distribution of the original study: March 6, 2025 / 6:34 a.m. / GMT
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
JPMorgan leaves Bayer at 'Neutral' - Target 25 euros
NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained its rating for Bayer at "Neutral" following its quarterly results, with a price target of €25. The positive surprise is solely due to lower long-term incentives (LTI) for executives, analyst Richard Vosser wrote on Wednesday after the figures were released. The outlook underpins the consensus./ag/edh
Publication of the original study: March 5, 2025 / 8:42 a.m. / GMT
First distribution of the original study: March 5, 2025 / 8:42 a.m. / GMT
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Deutsche Bank Research maintains Bayer's 'Hold' rating - target €23
FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research has maintained its "Hold" rating for Bayer following its quarterly results, with a price target of €23. The pharmaceutical and agrochemical company's sales and earnings figures exceeded forecasts, analyst Falko Friedrichs wrote in his initial reaction on Wednesday. The outlook for 2025 is in line with expectations./edh/ag
Publication of the original study: March 5, 2025 / Time not specified in the study / CET
First distribution of the original study: March 5, 2025 / 8:21 a.m. / CET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
UBS maintains Bayer at 'Neutral' - Target 22 euros
ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for Bayer at "Neutral" with a price target of €22. Analyst Jo Walton wrote on Tuesday that he expects a rather positive outlook for Bayer's crop protection business (CropScience) in light of the company's upcoming annual results. He also referred to the optimism recently expressed by competitor Corteva./ajx/mis
Publication of the original study: February 24, 2025 / 6:21 PM / GMT First distribution of the original study: February 24, 2025 / 6:21 PM / GMT
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
JPMorgan leaves Bayer at 'Neutral' - Target 25 euros
NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained its rating for Bayer at "Neutral" with a price target of €25 ahead of the company's quarterly results expected on March 5. Furthermore, the stock is currently on its "Catalyst Watch" list. The agrochemical and pharmaceutical company's targets for 2025 could continue to lead to a declining consensus estimate for earnings per share in its core business, analyst Richard Vosser wrote in a report released Wednesday. This was despite operating profit expectations appearing to be better substantiated./ck/tih
Publication of the original study: February 12, 2025 / 00:36 / GMT
First distribution of the original study: February 12, 2025 / 00:36 / GMT
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Berenberg maintains Bayer on 'Hold' - target 22 euros
HAMBURG (dpa-AFX Analyst) - Private bank Berenberg has maintained its rating for Bayer at "Hold" with a price target of €22. For investors in European chemical stocks, there are two ways to "wait and see," especially with regard to diversified chemical companies, analyst Sebastian Bray wrote in an industry report published Monday. He sees a short wait in view of a possible imminent revaluation. He cited fiscal stimulus in the US and China, more modest US tariffs than feared, and new political support for the chemical industry in Germany and China as reasons. Bray expects a waiting period beyond 2025 until profits can benefit again from lower energy costs in Europe or reforms in Germany that promote competitiveness./ck
Publication of the original study: January 24, 2025 / 6:03 p.m. / GMT
First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Bernstein maintains Bayer at 'Market Perform' - Target 30 euros
NEW YORK (dpa-AFX Analyst) - US analyst Bernstein Research has maintained its rating for Bayer at "Market-Perform" with a price target of €30. Although concerns about potential burdens from the Trump administration's healthcare policy have weighed somewhat on the European pharmaceutical sector towards the end of 2024, analyst Florent Cespedes remains optimistic in the medium term in a 2025 outlook published Tuesday. The reasons include good growth prospects given demographic developments and the industry's innovative strength, attractive stock valuations overall, and cash generation. His favorites are AstraZeneca, followed by Sanofi and Novartis./mis/bek
Publication of the original study: January 6, 2025 / 5:00 a.m. / UTC
First distribution of the original study: January 7, 2025 / 5:21 p.m. / UTC
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
JPMorgan leaves Bayer at 'Neutral' - Target 25 euros
NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained a "Neutral" rating on Bayer with a price target of €25. Given several key patent expirations, the coming year for European pharmaceutical companies is likely to be characterized by innovations from their product pipelines, analyst Richard Vosser wrote in an outlook published Tuesday. His preferred industry giants are Novo Nordisk and AstraZeneca, and from the life sciences sector, Merck KGaA, among others. Bayer, in turn, also has "Negative Catalyst Watch" status, with Vosser expressing his pessimistic expectations for the upcoming financial results in March. 2025 should be another difficult year for the group.
Publication of the original study: December 2, 2024 / 8:11 p.m. / GMT. First distribution of the original study: December 3, 2024 / 12:15 a.m. / GMT
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
UBS lowers target for Bayer to 22 euros - 'Neutral'
ZURICH (dpa-AFX Analyst) - Swiss bank UBS has lowered its price target for Bayer from €30 to €22, but left its rating at "Neutral." Analyst Jo Walton adjusted his estimates on Wednesday evening to reflect the Leverkusen-based company's weak outlook. This results in a 16 percent lower earnings forecast for 2025./ag/zb
Publication of the original study: November 20, 2024 / 8:45 p.m. / GMT
First distribution of the original study: November 21, 2024 / Time not specified in study / GMT
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Stifel lowers target for Bayer to 28 euros - 'Hold'
FRANKFURT (dpa-AFX Analyst) - The investment bank Stifel has lowered its price target for Bayer from €36 to €28 and maintained its "Hold" rating. Analyst Andreas Heine, in a study released Wednesday, pointed to his lowered earnings expectations for 2025. The headwinds the chemical and pharmaceutical company is experiencing from generics with its blockbuster Xarelto product intensified further in the third quarter. In addition, the US approval of the weed killer Dicamba is being delayed. While there are good reasons why 2025 should mark the low point for Bayer, he noted that the decline in earnings is likely to be negative. However, over the next year, uncertainty remains high, also due to the US legal disputes./tih/tav
Publication of the original study: November 19, 2024 / 11:31 AM / EST
First distribution of the original study: November 19, 2024 / 11:31 AM / EST
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Berenberg lowers target for Bayer to 22 euros - 'Hold'
HAMBURG (dpa-AFX Analyst) - Private bank Berenberg has lowered its price target for Bayer from €28 to €22, but maintained its "Hold" rating. Two aspects would be necessary for a sustained share price increase for the pharmaceutical company, wrote analyst Sebastian Bray in his assessment published on Tuesday. First, an end to the long-term downward cycle in earnings estimates, and second, a conclusion to the legal proceedings in the US, either through decisive victories or acceptable settlements. None of this appears imminent./tih/ag
Publication of the original study: November 18, 2024 / 9:44 PM / GMT
First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
JPMorgan lowers target for Bayer to 25 euros - 'Neutral'
NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has lowered its price target for Bayer from €34 to €25, but left its rating at "Neutral." The bottom could be reached in 2025, wrote analyst Richard Vosser in his review of the quarterly report published on Friday. Whether the Leverkusen-based company returns to growth in 2026 depends, according to the expert, on a turnaround in the agricultural sector. However, this is currently difficult to calculate./ag/tih
Publication of the original study: November 15, 2024 / 00:15 / GMT
First distribution of the original study: November 15, 2024 / 00:15 / GMT
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Deutsche Bank Research lowers target for Bayer to 23 euros - 'Hold'
FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research has lowered its price target for Bayer from €29 to €23, but maintained its "Hold" rating. The situation remains difficult for the Leverkusen-based company, wrote analyst Falko Friedrichs in his review of the quarterly report published on Thursday. No rapid improvement is in sight./ag/mis
Publication of the original study: November 14, 2024 / Time not specified in study / CET
First distribution of the original study: November 14, 2024 / 08:15 / CET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
UBS maintains Bayer at 'Neutral' - target 30 euros
ZURICH (dpa-AFX Analyst) - UBS has maintained its rating for Bayer at "Neutral" following a meeting with the CFO at the Swiss bank's investor conference. The price target for the chemical and pharmaceutical company remains unchanged at €30. Wolfgang Nickl signaled his long-term confidence despite increasing short-term challenges, wrote analyst Jo Walton in a study released Wednesday./tih/la
Publication of the original study: November 13, 2024 / 12:56 / GMT
First distribution of the original study: November 13, 2024 / 12:56 / GMT
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Deutsche Bank Research maintains Bayer's 'Hold' rating - target 29 euros
FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research has maintained a "Hold" rating on Bayer following its quarterly results, with a price target of €29. The pharmaceutical and agrochemical company has disappointed across the board, wrote analyst Falko Friedrichs in a study published Wednesday./gl/tih
Publication of the original study: November 13, 2024 / 8:09 a.m. / CET First distribution of the original study: Date not specified in study / Time not specified in study / CET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Goldman lowers target for Bayer to 27 euros - 'Neutral'
NEW YORK (dpa-AFX Analyst) - US investment bank Goldman Sachs lowered its price target for Bayer from €30 to €27, but maintained its rating at "Neutral." 2025 will be another difficult year operationally, wrote analyst James Quigley in his reaction to the interim report published on Wednesday. A final ruling from the US Supreme Court could significantly ease the burden of the gylophosate litigation. Quigley, however, considers the likelihood of this to be low./ag/mis
Publication of the original study: November 13, 2024 / 5:40 a.m. / GMT
First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Barclays lowers target for Bayer to 22 euros - 'Equal Weight'
LONDON (dpa-AFX Analyst) - British investment bank Barclays lowered its price target for Bayer from €26 to €22, but maintained its rating at "Equal Weight." Cautious comments for 2025 for all three business units underscored the difficult situation, analyst Emily Field wrote Tuesday evening after the quarterly report and conference call. It adjusted its estimates./ag/stk
Publication of the original study: November 12, 2024 / 8:33 PM / GMT
First distribution of the original study: November 13, 2024 / 4:00 AM / GMT
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Goldman maintains Bayer at 'Neutral' - target 30 euros
NEW YORK (dpa-AFX Analyst) - US investment bank Goldman Sachs has maintained its rating for Bayer at "neutral" with a price target of €30 following the company's earnings release. The chemical and pharmaceutical company missed expectations in the third quarter, analyst James Quigley wrote in a report released Tuesday. Cautious comments regarding the 2025 fiscal year could weigh on consensus forecasts, the expert added./tih/mis
Publication of the original study: November 12, 2024 / 7:50 a.m. / GMT
First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
UBS maintains Bayer at 'Neutral' - target 30 euros
ZURICH (dpa-AFX Analyst) - The Swiss major bank UBS has left its rating for Bayer at "Neutral" with a price target of 30 euros after the quarterly figures. The pharmaceutical and agrochemical group's revenue and, above all, its operating result (adjusted EBITDA) missed consensus estimates, wrote analyst Jo Walton in an initial response released Tuesday./edh/tih
Publication of the original study: November 12, 2024 / 08:06 / GMT
First distribution of the original study: November 12, 2024 / 08:06 / GMT
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
JPMorgan maintains Bayer at 'Neutral' - Target 34 euros
NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained its rating for Bayer at "Neutral" with a price target of €34 following its quarterly results. Analyst Richard Vosser wrote in an initial reaction released Tuesday that the results were weaker than expected. In addition, the revised annual targets and the outlook for 2025 are likely to lead to declining consensus estimates./edh/mis
Publication of the original study: November 12, 2024 / 7:56 a.m. / GMT
First distribution of the original study: November 12, 2024 / 7:56 a.m. / GMT
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Jefferies maintains Bayer on 'Hold' - target 29 euros
NEW YORK (dpa-AFX Analyst) - The analyst firm Jefferies has maintained its rating for Bayer at "Hold" with a price target of €29 after the company released its results. Adjusted operating profit (EBITDA) missed the analyst consensus by 5 percent, wrote analyst Charlie Bentley in a report released Tuesday. The outlook has been lowered, particularly for the agricultural business./tih/mis
Publication of the original study: November 12, 2024 / 2:02 AM / ET
First distribution of the original study: November 12, 2024 / 2:02 AM / ET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
UBS maintains Bayer at 'Neutral' - target 30 euros
ZURICH (dpa-AFX Analyst) - The Swiss major bank UBS has maintained its rating for Bayer at "Neutral" with a price target of €30. The third quarter is normally a loss-making quarter for the Crop Science division, but a strong one for the Leverkusen-based company's pharmaceutical business, wrote analyst Jo Walton on Thursday in light of the upcoming financial results. Bayer's initial outlook for 2025 was below market expectations./ajx/jha/
Publication of the original study: November 7, 2024 / 4:30 PM / GMT
First distribution of the original study: November 7, 2024 / 4:30 PM / GMT
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
JPMorgan maintains Bayer at 'Neutral' - Target 34 euros
NEW YORK (dpa-AFX Analyst) - The US bank JPMorgan has left Bayer at "Neutral" with a price target of 34 euros. For the quarterly figures due on November 12, his estimates for core earnings per share (Core EPS) and even more so for operating profit (EBITDA) are above the consensus estimates recently published by the group, wrote analyst Richard Vosser in an outlook released on Monday.
Publication of the original study: October 28, 2024 / 3:15 p.m. / GMT First distribution of the original study: October 28, 2024 / 3:15 p.m. / GMT
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
JPMorgan maintains Bayer at 'Neutral' - Target 34 euros
NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained its rating for Bayer at "Neutral" ahead of its quarterly results, with a price target of €34. An expected weaker performance in the agrochemicals business is likely to have been offset by a better performance in the pharmaceuticals division, analyst Richard Vosser wrote in a study released Tuesday. However, due to negative currency effects, consensus earnings estimates for 2024 could decline./edh/bek
Publication of the original study: October 14, 2024 / 7:53 PM / BST
First distribution of the original study: October 15, 2024 / 12:15 AM / BST
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Goldman maintains Bayer at 'Neutral' - target 30 euros
NEW YORK (dpa-AFX Analyst) - US investment bank Goldman Sachs has maintained its rating for Bayer at "Neutral" with a price target of €30. The Leverkusen-based company must decide which case it wants to take to the Supreme Court, wrote analyst James Quigley in his commentary published Friday on another lost glyphosate lawsuit in the US. If the highest US court then takes up the matter, it could represent enormous progress toward finally getting rid of the burden. The outcome, however, remains unclear./ag/tih
Publication of the original study: October 11, 2024 / 9:05 a.m. / BST
First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Goldman maintains Bayer at 'Neutral' - target 30 euros
NEW YORK (dpa-AFX Analyst) - US investment bank Goldman Sachs has maintained its rating for Bayer at "Neutral" with a price target of €30. A normalization in the agricultural sector is overshadowing the pharmaceutical strength, wrote analyst James Quigley in his commentary published Friday. Legal disputes also remain a burden./ag/gl
Publication of the original study: October 11, 2024 / 5:24 a.m. / BST First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Berenberg maintains Bayer on 'Hold' - target 28 euros
HAMBURG (dpa-AFX Analyst) - Private bank Berenberg has maintained its "Hold" rating for Bayer with a price target of €28. The company intends to further improve its earnings growth, analyst Sebastian Bray wrote in a study released Wednesday following a discussion with Bayer's CFO at an investment conference. Further goals include reducing the complexity of the corporate structure, lowering debt, and resolving legal disputes./mf/ajx
Publication of the original study: September 24, 2024 / 1:47 PM / GMT
First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
JPMorgan maintains Bayer at 'Neutral' - Target 34 euros
NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained its rating for Bayer at "Neutral" with a price target of €34. Nubeqa's data in advanced, hormone-sensitive prostate cancer confirm the drug's potential, wrote analyst Richard Vosser in his commentary on Monday's presentation at the ESMO Congress. However, they are likely already included in the consensus./ag/bek
Publication of the original study: September 16, 2024 / 11:11 AM / BST
First distribution of the original study: September 16, 2024 / 11:11 AM / BST
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Goldman maintains Bayer at 'Neutral' - target 30 euros
NEW YORK (dpa-AFX Analyst) - US investment bank Goldman Sachs has maintained its rating for Bayer at "Neutral" with a price target of €30. The data presented by the Leverkusen-based company at the World Lung Cancer Conference (WCLC) appeared solid, wrote analyst James Quigley in his commentary published on Tuesday. However, questions regarding competitiveness and compatibility remain unanswered./ag/la
Publication of the original study: September 10, 2024 / 5:47 a.m. / BST
First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
UBS maintains Bayer at 'Neutral' - target 30 euros
ZURICH (dpa-AFX Analyst) - Following a conference held by the major Swiss bank, UBS maintained its rating for Bayer at "Neutral" with a price target of €30. The volume outlook was consistently the focus of the discussions, wrote analyst Geoff Haire in his industry commentary on chemical stocks published on Monday. Most companies reported modest progress in the third quarter and anticipated normal seasonality in the final quarter. Clients are currently continuing to pay attention to low inventory levels. There are signs of improvement in some areas, but there are downside risks to the business in the automotive sector./tih/ag
Publication of the original study: September 6, 2024 / 7:21 PM / GMT
First distribution of the original study: September 6, 2024 / 7:21 PM / GMT
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Goldman maintains Bayer at 'Neutral' - target 30 euros
NEW YORK (dpa-AFX Analyst) - Goldman Sachs has maintained a "Neutral" rating on Bayer with a price target of €30. Based on detailed data from the Phase III "Finearts-HF" trial, the drug finerenone (brand name Kerendia) for the treatment of heart failure appears competitive, analyst James Quigley wrote in a report published Monday. The expert expects peak annual sales of €2.3 billion, which should be achieved with consistent growth over a seven-year lead time. The increase could possibly be even faster./mis/ck
Publication of the original study: September 2, 2024 / 5:05 a.m. / BST
First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
UBS maintains Bayer at 'Neutral' - target 30 euros
ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for Bayer at "Neutral" with a price target of €30. Results from a third phase of a trial with the heart failure drug candidate finerenone (Kerendia) are positive, analyst Jo Walton wrote in a study released Monday. He expects the drug to be approved./tih/mis
Publication of the original study: September 2, 2024 / 12:37 / GMT
First distribution of the original study: September 2, 2024 / 12:37 / GMT
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
JPMorgan maintains Bayer at 'Neutral' - Target 34 euros
NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained its rating for Bayer at "Neutral" with a price target of €34. Based on the detailed data from the Phase III "Finearts-HF" study, finerenone (brand name Kerendia) is likely to be approved for the treatment of heart failure, analyst Richard Vosser wrote in a study published Monday. This should have a positive impact on the shares./mis/tih
Publication of the original study: September 1, 2024 / 7:57 PM / BST
First distribution of the original study: September 2, 2024 / 12:15 AM / BST
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.